A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer

NCT ID: NCT01215526

Last Updated: 2015-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

274 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients with advanced hormone-dependent prostate carcinoma that are eligible for hormone therapy

Exclusion Criteria

\- Patients with a contraindication for prescription of Firmagon®
Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Development Support

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jeroen Bosch Ziekenhuis, locatie Carolus

's-Hertogenbosch, , Netherlands

Site Status

Flevoziekenhuis

Almere Stad, , Netherlands

Site Status

Bovenij Ziekenhuis

Amsterdam, , Netherlands

Site Status

Wilhelminaziekenhuis

Assen, , Netherlands

Site Status

Rode Kruis Ziekenhuis

Beverwijk, , Netherlands

Site Status

Tergooiziekenhuizen

Blaricum, , Netherlands

Site Status

Amphia Ziekenhuis

Breda, , Netherlands

Site Status

Ljsselland Ziekenhuis

Capelle aan den IJssel, , Netherlands

Site Status

Reinier de Graaf Groep

Delft, , Netherlands

Site Status

Deventer Ziekenhuis

Deventer, , Netherlands

Site Status

Slingeland Ziekenhuis

Doetinchem, , Netherlands

Site Status

Alb.Schweitzer Ziekenhuis, loc. Dordwijk

Dordrecht, , Netherlands

Site Status

Gelderse Vallei, loc. Barneveld

Ede, , Netherlands

Site Status

Admiraal de Ruyter Ziekenhuis

Flushing, , Netherlands

Site Status

St. Anna Ziekenhuis

Geldrop, , Netherlands

Site Status

Admiraal de Ruyter Ziekenhuis

Goes, , Netherlands

Site Status

Rivas Beatrixziekenhuis

Gorinchem, , Netherlands

Site Status

Het Groene Hart Ziekenhuis

Gouda, , Netherlands

Site Status

Buitenpolikliniek

Groenlo, , Netherlands

Site Status

Martini Ziekenhuis

Groningen, , Netherlands

Site Status

Ziekenhuis St Jansdal

Harderwijk, , Netherlands

Site Status

Elkerliek Ziekenhuis

Helmond, , Netherlands

Site Status

Tergooiziekenhuizen

Hilversum, , Netherlands

Site Status

Medisch Centrum Leeuwarden

Leeuwarden, , Netherlands

Site Status

LUMC

Leiden, , Netherlands

Site Status

Rijnland Ziekenhuis

Leiderdorp, , Netherlands

Site Status

MUMC

Maastricht, , Netherlands

Site Status

Ziekenhuis Bernhoven, loc. Oss

Oss, , Netherlands

Site Status

Waterland Ziekenhuis

Purmerend, , Netherlands

Site Status

Franciscus Ziekenhuis

Roosendaal, , Netherlands

Site Status

Havenziekenhuis

Rotterdam, , Netherlands

Site Status

Vlietland Ziekenhuis

Rotterdam, , Netherlands

Site Status

Orbis Medisch Centrum

Sittard-Geleen, , Netherlands

Site Status

Alb. Schweitzer Ziekenhuis loc. Sliedrecht

Sliedrecht, , Netherlands

Site Status

Antonius Ziekenhuis

Sneek, , Netherlands

Site Status

Ruwaard v Putten/vWeel Bethesda Zkhs

Spijkenisse, , Netherlands

Site Status

Zorgzaam Ziekenhuis

Terneuzen, , Netherlands

Site Status

Hagaziekenhuis loc. Leyweg

The Hague, , Netherlands

Site Status

Hagaziekenhuis loc. Sportlaan

The Hague, , Netherlands

Site Status

Ziekenhuis Rivierenland

Tiel, , Netherlands

Site Status

Antonius Ziekenhuis, loc. Oudenrijn

Utrecht, , Netherlands

Site Status

Diakonessenhuis Utrecht

Utrecht, , Netherlands

Site Status

Ziekenhuis Bernhoven, loc. Veghel

Veghel, , Netherlands

Site Status

Maxima Medisch Centrum

Veldhoven, , Netherlands

Site Status

St. Jans Gasthuis

Weert, , Netherlands

Site Status

Albert Schweitzer Ziekenhuis

Zwijndrecht, , Netherlands

Site Status

Isala Klinieken

Zwolle, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FE200486 CS46

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Firmagon (Degarelix) Intermittent Therapy
NCT01512472 TERMINATED PHASE4